You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBuspirone
Accession NumberDB00490  (APRD00222)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to diazepam. [PubChem]
Structure
Thumb
Synonyms
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
Buspiron
Buspirona
Buspirone
Buspironum
External Identifiers
  • MJ 90221-1
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Buspar Tab 10mgTablet10 mgOralBristol Myers Squibb Canada1989-12-312010-11-12Canada
BuspironeTablet10 mgOralSanis Health Inc2016-02-17Not applicableCanada
Buspirone-10 - Tab 10mgTablet10 mgOralPro Doc Limitee1997-01-15Not applicableCanada
BustabTablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
BustabTablet5 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Co BuspironeTablet10 mgOralCobalt Pharmaceuticals Company2005-11-092012-08-02Canada
Dom-buspironeTablet10 mgOralDominion Pharmacal1999-10-25Not applicableCanada
Ftp-buspironeTablet10 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
LinbuspironeTablet10 mgOralLinson Pharma Co.1996-12-312006-05-29Canada
Mylan-buspironeTablet10 mgOralMylan Pharmaceuticals Ulc1997-03-132010-08-04Canada
Nu-buspirone - Tab 10mgTablet10 mgOralNu Pharm Inc1996-12-312012-09-04Canada
Penta-buspironeTablet10 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-buspironeTablet5 mgOralPharmascience Inc1997-06-05Not applicableCanada
PMS-buspironeTablet10 mgOralPharmascience Inc1997-05-26Not applicableCanada
Ratio-buspironeTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited1998-06-102010-05-17Canada
Riva-buspirone 10 mgTablet10 mgOralLaboratoire Riva Inc2003-03-03Not applicableCanada
Teva-buspironeTablet10 mgOralTeva Canada Limited1997-09-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-buspirone - Tab 10mgTablet10 mgOralApotex Inc1996-12-31Not applicableCanada
BusparTablet5 mg/1OralDIRECT RX2016-05-03Not applicableUs
BuspironeTablet10 mg/1OralSTAT Rx USA LLC2002-03-01Not applicableUs
Buspirone HClTablet10 mg/1OralProficient Rx LP2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralClinical Solutions Wholesale2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralImpax Generics2001-03-282016-11-15Us
Buspirone HClTablet15 mg/1OralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Buspirone HClTablet10 mg/1OralA S Medication Solutions2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralImpax Generics2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralDispensing Solutions, Inc.2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HClTablet10 mg/1OralCardinal Health2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1Oralbryant ranch prepack2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Buspirone HClTablet10 mg/1OralDispensing Solutions, Inc.2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralClinical Solutions Wholesale2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralImpax Generics2001-03-282016-11-15Us
Buspirone HClTablet15 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Buspirone HClTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2013-06-24Not applicableUs
Buspirone HClTablet10 mg/1OralImpax Generics2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralUnit Dose Services2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HClTablet15 mg/1OralImpax Generics2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralTYA Pharmaceuticals2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralProficient Rx LP2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralSTAT Rx USA LLC2001-03-28Not applicableUs
Buspirone HClTablet5 mg/1OralImpax Generics2001-03-282016-11-15Us
Buspirone HClTablet10 mg/1OralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1Oralbryant ranch prepack2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HClTablet10 mg/1OralTYA Pharmaceuticals2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralA S Medication Solutions2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralMedsource Pharmaceuticals2001-03-28Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralMylan Institutional Inc.2002-03-25Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralMc Kesson Contract Packaging2011-11-07Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralRebel Distributors Corp2010-12-23Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralREMEDYREPACK INC.2010-12-072016-10-13Us
Buspirone HydrochlorideTablet15 mg/1OralClinical Solutions Wholesale, Llc2014-05-03Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralTeva Pharmaceuticals Usa, Inc.2002-02-28Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralMylan Pharmaceuticals Inc.2002-03-01Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2015-01-20Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralDIRECT RX2014-01-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralAphena Pharma Solutions Tennessee, Llc2001-03-28Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-06-01Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2013-05-03Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralPreferred Pharmaceuticals Inc.2015-08-19Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralPar Pharmaceutical Inc.2012-04-23Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2010-12-152016-10-13Us
Buspirone HydrochlorideTablet7.5 mg/1OralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralMylan Pharmaceuticals Inc.2001-06-28Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralMylan Institutional Inc.2002-03-25Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralProficient Rx LP2002-03-01Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralSTAT Rx USA LLC2010-07-01Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralMc Kesson Contract Packaging2011-11-21Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralAv Kare, Inc.2013-08-28Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralNu Care Pharmaceuticals, Inc.2016-11-09Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralMylan Pharmaceuticals Inc.2013-07-08Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2011-05-12Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-04-23Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralTeva Pharmaceuticals Usa, Inc.2002-02-28Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralA S Medication Solutions2001-03-28Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone HydrochlorideTablet30 mg/1Oralbryant ranch prepack2010-12-23Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-02-09Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-03-21Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2013-05-02Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralPhysicians Total Care, Inc.2012-04-30Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2015-01-12Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralSTAT Rx USA LLC2011-10-05Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralCardinal Health2010-03-31Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralAidarex Pharmaceuticals LLC2002-02-28Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralAv Kare, Inc.2013-10-17Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralMylan Institutional Inc.2002-12-01Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone HydrochlorideTablet15 mg/1Oralbryant ranch prepack2002-03-01Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralCarilion Materials Management2002-02-28Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralREMEDYREPACK INC.2014-12-10Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralA S Medication Solutions2014-05-03Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralA S Medication Solutions2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2010-12-152016-10-13Us
Buspirone HydrochlorideTablet10 mg/1OralMylan Pharmaceuticals Inc.2002-03-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2011-03-23Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralPhysicians Total Care, Inc.2004-12-21Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-02-28Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralTeva Pharmaceuticals Usa, Inc.2002-03-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2015-06-22Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2001-03-28Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralA S Medication Solutions2002-03-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2011-10-132017-11-03Us
Buspirone HydrochlorideTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-03-21Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralMylan Institutional Inc.2001-04-15Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralDIRECT RX2015-01-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone HydrochlorideTablet5 mg/1OralCardinal Health2010-03-31Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralAidarex Pharmaceuticals LLC2002-03-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2015-01-12Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralA S Medication Solutions2014-05-03Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-25Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralCardinal Health2001-03-28Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralCarilion Materials Management2002-02-28Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralRebel Distributors Corp2009-09-09Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralPreferred Pharmaceuticals Inc.2015-10-08Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralTeva Pharmaceuticals Usa, Inc.2004-03-26Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2016-05-18Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2010-12-152016-11-15Us
Buspirone HydrochlorideTablet5 mg/1OralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralMylan Pharmaceuticals Inc.2001-03-28Not applicableUs
Buspirone HydrochlorideTablet30 mg/1OralREMEDYREPACK INC.2012-03-292016-10-13Us
Buspirone HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralMajor Pharmaceuticals2009-08-09Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralH.J. Harkins Company, Inc.2010-12-23Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralClinical Solutions Wholesale, Llc2014-05-03Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone HydrochlorideTablet10 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone HydrochlorideTablet7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-07-08Not applicableUs
Buspirone HydrochlorideTablet15 mg/1OralREMEDYREPACK INC.2011-08-232017-11-11Us
Buspirone HydrochlorideTablet15 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnsialRontag
AnxironValeant
AnxutEisai
BesparNot Available
BuscalmWockhardt
BuspHexal
BusparBristol-Myers Squibb
BusponDeva
DalpasBiotech
EpsilatCoup
PasrinAspen Pharmacare
SpamilanAnpharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Buspirone Hydrochloride
33386-08-2
Thumb
  • InChI Key: RICLFGYGYQXUFH-UHFFFAOYSA-N
  • Monoisotopic Mass: 421.224453
  • Average Mass: 421.964
DBSALT000313
Categories
UNIITK65WKS8HL
CAS number36505-84-7
WeightAverage: 385.5031
Monoisotopic: 385.247775261
Chemical FormulaC21H31N5O2
InChI KeyQWCRAEMEVRGPNT-UHFFFAOYSA-N
InChI
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
IUPAC Name
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
SMILES
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
Pharmacology
IndicationFor the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.
Structured Indications
PharmacodynamicsBuspirone is used in the treatment of generalized anxiety where it has advantages over other antianxiety drugs because it does not cause sedation (drowsiness) and does not cause tolerance or physical dependence. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. in vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo when tested in preclinical models. Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.
Mechanism of actionBuspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 1AProteinyes
partial agonist
HumanP08908 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Related Articles
AbsorptionRapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.
Volume of distributionNot Available
Protein binding95% (approximately 70% bound to albumin, 30% bound to alpha 1 -acid glycoprotein)
Metabolism

Metabolized hepatically, primarily by oxidation by cytochrome P450 3A4 producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP)

SubstrateEnzymesProduct
Buspirone
1-PyrimidinylpiperazineDetails
Buspirone
Buspirone N-oxideDetails
Buspirone
3′-HydroxybuspironeDetails
Buspirone
5-HydroxybuspironeDetails
Buspirone
6'-HydroxybuspironeDetails
Route of eliminationIn a single-dose study using 14C-labeled buspirone, 29% to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites; fecal excretion accounted for 18% to 38% of the dose.
Half life2-3 hours (although the action of a single dose is much longer than the short halflife indicates).
ClearanceNot Available
ToxicityOral, rat LD50 = 136 mg/kg. Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Buspirone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Buspirone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Buspirone can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Buspirone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Buspirone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Buspirone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Buspirone.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Buspirone.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Buspirone is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Buspirone.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Buspirone is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Buspirone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Buspirone.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Buspirone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buspirone.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Buspirone.Approved, Investigational
AmiodaroneThe metabolism of Buspirone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buspirone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Amobarbital.Approved, Illicit
AmorolfineThe metabolism of Buspirone can be decreased when combined with Amorolfine.Approved
AmoxapineBuspirone may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amperozide.Experimental
Amphotericin BThe metabolism of Buspirone can be decreased when combined with Amphotericin B.Approved, Investigational
AN2690The metabolism of Buspirone can be decreased when combined with AN2690.Investigational
AnidulafunginThe metabolism of Buspirone can be decreased when combined with Anidulafungin.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Buspirone.Approved
AprepitantThe serum concentration of Buspirone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Buspirone.Approved, Investigational
ArtemetherThe metabolism of Buspirone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Asenapine.Approved
AtazanavirThe metabolism of Buspirone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Buspirone.Approved
AtomoxetineThe metabolism of Buspirone can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Buspirone.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Azaperone.Vet Approved
AzelastineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Buspirone is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Buspirone is combined with Baclofen.Approved
Bafilomycin A1The metabolism of Buspirone can be decreased when combined with Bafilomycin A1.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.Illicit
BenmoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Buspirone can be decreased when combined with Benzoic Acid.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Buspirone.Approved, Vet Approved
BetaxololThe metabolism of Buspirone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Buspirone can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Buspirone is combined with Bifeprunox.Investigational
BifonazoleThe metabolism of Buspirone can be decreased when combined with Bifonazole.Approved
BoceprevirThe metabolism of Buspirone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Buspirone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Buspirone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Buspirone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buspirone.Approved, Investigational
BuprenorphineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Buspirone can be decreased when combined with Bupropion.Approved
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Buspirone is combined with Butamben.Approved
ButenafineThe metabolism of Buspirone can be decreased when combined with Butenafine.Approved
ButethalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butethal.Approved, Illicit
ButoconazoleThe metabolism of Buspirone can be decreased when combined with Butoconazole.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Buspirone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Buspirone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Buspirone.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Buspirone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Buspirone.Approved
CandicidinThe metabolism of Buspirone can be decreased when combined with Candicidin.Withdrawn
CarbamazepineThe metabolism of Buspirone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Buspirone can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Buspirone.Approved
CariprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Caroxazone.Withdrawn
CaspofunginThe metabolism of Buspirone can be decreased when combined with Caspofungin.Approved
CelecoxibThe metabolism of Buspirone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Buspirone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Buspirone.Withdrawn
CeruleninThe metabolism of Buspirone can be decreased when combined with Cerulenin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Buspirone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Buspirone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChloroxineThe metabolism of Buspirone can be decreased when combined with Chloroxine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Buspirone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Buspirone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe metabolism of Buspirone can be decreased when combined with Ciclopirox.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Buspirone.Approved
CinacalcetThe metabolism of Buspirone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Buspirone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Buspirone.Approved
CitalopramBuspirone may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Buspirone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Buspirone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Buspirone is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Buspirone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Buspirone.Approved, Investigational
ClomipramineBuspirone may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Buspirone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Buspirone.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Buspirone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Buspirone.Approved
CobicistatThe serum concentration of Buspirone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Buspirone.Approved
CocaineThe metabolism of Buspirone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Buspirone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Buspirone.Approved
ConivaptanThe serum concentration of Buspirone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buspirone.Approved
CordycepinThe metabolism of Buspirone can be decreased when combined with Cordycepin.Investigational
CrizotinibThe metabolism of Buspirone can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Buspirone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone.Approved
DabrafenibThe serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Buspirone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Buspirone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Buspirone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.Investigational
DarifenacinThe metabolism of Buspirone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Buspirone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Buspirone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Buspirone.Approved
Decanoic AcidThe metabolism of Buspirone can be decreased when combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Buspirone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Buspirone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineBuspirone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Buspirone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Buspirone.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buspirone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Buspirone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Buspirone.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Buspirone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Buspirone.Illicit
DiltiazemThe metabolism of Buspirone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Buspirone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Buspirone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Buspirone.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Buspirone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Buspirone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Buspirone.Approved, Investigational
DoxycyclineThe metabolism of Buspirone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Buspirone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Illicit
DronedaroneThe metabolism of Buspirone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Drotebanol.Experimental, Illicit
DuloxetineBuspirone may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Buspirone is combined with ECGONINE METHYL ESTER.Experimental
EconazoleThe metabolism of Buspirone can be decreased when combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Buspirone.Approved
EfavirenzThe serum concentration of Buspirone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Buspirone can be decreased when combined with Efinaconazole.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Buspirone.Approved, Investigational
EliglustatThe metabolism of Buspirone can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Buspirone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Buspirone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Buspirone.Approved, Investigational
ErythromycinThe metabolism of Buspirone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramBuspirone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Buspirone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Buspirone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Buspirone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Buspirone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buspirone.Approved
EthanolBuspirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buspirone.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buspirone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Buspirone.Approved
EtoperidoneBuspirone may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Buspirone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Buspirone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Buspirone.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Buspirone.Approved
EzogabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineBuspirone may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Buspirone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Buspirone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Buspirone.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.Approved
FluconazoleThe metabolism of Buspirone can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Buspirone can be decreased when combined with Flucytosine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunitrazepam.Approved, Illicit
FluoxetineBuspirone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Buspirone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluticasone Propionate.Approved
FluvoxamineBuspirone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Buspirone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Buspirone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Buspirone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Buspirone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Buspirone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Buspirone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Buspirone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Buspirone.Approved
GepironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Buspirone is combined with Glutethimide.Approved, Illicit
GlyphosateThe metabolism of Buspirone can be decreased when combined with Glyphosate.Experimental
GranisetronGranisetron may increase the serotonergic activities of Buspirone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Buspirone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Buspirone.Withdrawn
GriseofulvinThe metabolism of Buspirone can be decreased when combined with Griseofulvin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Buspirone.Approved
HaloproginThe metabolism of Buspirone can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Buspirone is combined with Heroin.Approved, Illicit
HexetidineThe metabolism of Buspirone can be decreased when combined with Hexetidine.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Hydracarbazine.Approved
HydrocodoneBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Buspirone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Buspirone.Approved
IdelalisibThe serum concentration of Buspirone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.Approved
ImatinibThe metabolism of Buspirone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Buspirone.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Buspirone.Approved
IndalpineBuspirone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Buspirone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Buspirone.Approved, Investigational
Ioflupane I-123Buspirone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Buspirone.Approved, Investigational
IsavuconazoniumThe metabolism of Buspirone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Buspirone is combined with Isocarboxazid.Approved
IsoconazoleThe metabolism of Buspirone can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Buspirone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Buspirone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Buspirone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Buspirone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Buspirone.Approved, Vet Approved
JosamycinThe metabolism of Buspirone can be decreased when combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Buspirone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Buspirone can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Buspirone can be decreased when combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Buspirone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Buspirone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Buspirone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Buspirone.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Buspirone.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Buspirone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Buspirone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Buspirone is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Buspirone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomethadyl Acetate.Approved
LevomilnacipranBuspirone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Buspirone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Buspirone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Buspirone is combined with Linezolid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Buspirone.Approved
LopinavirThe metabolism of Buspirone can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Buspirone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Buspirone.Approved
LovastatinThe metabolism of Buspirone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Buspirone.Approved
Lu AA21004Buspirone may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Buspirone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Buspirone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Buspirone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Buspirone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Buspirone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Buspirone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Buspirone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Buspirone.Approved
MethotrimeprazineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.Approved
Methylene blueBuspirone may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Buspirone.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Buspirone.Approved, Investigational
MetyrosineBuspirone may increase the sedative activities of Metyrosine.Approved
MevastatinThe metabolism of Buspirone can be decreased when combined with Mevastatin.Experimental
MicafunginThe metabolism of Buspirone can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Buspirone can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Buspirone.Approved, Illicit
MifepristoneThe serum concentration of Buspirone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranBuspirone may increase the serotonergic activities of Milnacipran.Approved
MiltefosineThe metabolism of Buspirone can be decreased when combined with Miltefosine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Buspirone is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Buspirone.Approved
MirtazapineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Buspirone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Buspirone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Buspirone is combined with Moclobemide.Approved
ModafinilThe serum concentration of Buspirone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Molindone.Approved
MonensinThe metabolism of Buspirone can be decreased when combined with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Buspirone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buspirone.Approved, Investigational
MyxothiazolThe metabolism of Buspirone can be decreased when combined with Myxothiazol.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Buspirone.Approved
NafcillinThe serum concentration of Buspirone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Buspirone can be decreased when combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Buspirone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Buspirone.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Naratriptan.Approved, Investigational
NatamycinThe metabolism of Buspirone can be decreased when combined with Natamycin.Approved
NefazodoneBuspirone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Buspirone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Buspirone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Buspirone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Buspirone is combined with Nialamide.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Buspirone.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Buspirone.Approved
NilotinibThe metabolism of Buspirone can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Buspirone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrous oxide.Approved, Vet Approved
NitroxolineThe metabolism of Buspirone can be decreased when combined with Nitroxoline.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Buspirone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nortriptyline.Approved
NystatinThe metabolism of Buspirone can be decreased when combined with Nystatin.Approved, Vet Approved
OctamoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Octamoxin.Withdrawn
OlanzapineBuspirone may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Buspirone can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Buspirone can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Buspirone.Approved
OndansetronOndansetron may increase the serotonergic activities of Buspirone.Approved
OpiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Opium.Approved, Illicit
OrphenadrineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Buspirone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxetacaine.Investigational
OxiconazoleThe metabolism of Buspirone can be decreased when combined with Oxiconazole.Approved
OxprenololThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Buspirone.Approved, Vet Approved
pafuramidineThe metabolism of Buspirone can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Buspirone.Approved, Investigational
PanobinostatThe serum concentration of Buspirone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pargyline.Approved
ParoxetineBuspirone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.Approved
Peginterferon alfa-2bThe serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Buspirone can be decreased when combined with Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Buspirone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
PerazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Buspirone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Buspirone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoxypropazine.Withdrawn
PhenytoinThe metabolism of Buspirone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Buspirone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Buspirone is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Buspirone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Buspirone.Approved
PosaconazoleThe metabolism of Buspirone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBuspirone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Buspirone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Buspirone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Buspirone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Buspirone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Buspirone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Buspirone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Buspirone.Approved, Vet Approved
PromazineThe metabolism of Buspirone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Buspirone.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Buspirone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Buspirone.Approved
PSD502The risk or severity of adverse effects can be increased when Buspirone is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Buspirone.Approved
QuinidineThe metabolism of Buspirone can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Buspirone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Raclopride.Investigational
RadicicolThe metabolism of Buspirone can be decreased when combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Buspirone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Buspirone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Buspirone.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Buspirone.Approved
RifabutinThe serum concentration of Buspirone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Buspirone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Buspirone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Buspirone.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Buspirone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Ritanserin.Investigational
RitonavirThe metabolism of Buspirone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Buspirone.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Rizatriptan.Approved
RolapitantThe metabolism of Buspirone can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Buspirone.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Romifidine.Vet Approved
RopiniroleBuspirone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone.Approved
RotigotineBuspirone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Buspirone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Buspirone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Buspirone is combined with Sage 547.Investigational
Salicylhydroxamic AcidThe metabolism of Buspirone can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Buspirone can be decreased when combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Buspirone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Buspirone.Approved
SertaconazoleThe metabolism of Buspirone can be decreased when combined with Sertaconazole.Approved
SertindoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertindole.Approved, Withdrawn
SertralineBuspirone may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Buspirone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Buspirone.Approved
SiltuximabThe serum concentration of Buspirone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Buspirone can be increased when it is combined with Simeprevir.Approved
SinefunginThe metabolism of Buspirone can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Buspirone can be decreased when combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Buspirone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Buspirone.Approved
SolithromycinThe metabolism of Buspirone can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Buspirone.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Buspirone.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Buspirone.Experimental
St. John's WortThe serum concentration of Buspirone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Buspirone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.Approved, Investigational
SulconazoleThe metabolism of Buspirone can be decreased when combined with Sulconazole.Approved
SulfisoxazoleThe metabolism of Buspirone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Buspirone.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Sumatriptan.Approved, Investigational
SuvorexantBuspirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Buspirone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Buspirone.Approved
TandospironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Buspirone.Experimental
TavaboroleThe metabolism of Buspirone can be decreased when combined with Tavaborole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Buspirone.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Buspirone.Approved
TelaprevirThe metabolism of Buspirone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Buspirone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Buspirone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Buspirone.Approved
TerbinafineThe metabolism of Buspirone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Buspirone can be decreased when combined with Terconazole.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrodotoxin.Investigational
ThalidomideBuspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Buspirone can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.Approved
ThymolThe metabolism of Buspirone can be decreased when combined with Thymol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Buspirone.Approved
TiclopidineThe metabolism of Buspirone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Buspirone.Approved
TioconazoleThe metabolism of Buspirone can be decreased when combined with Tioconazole.Approved
TipranavirThe metabolism of Buspirone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe metabolism of Buspirone can be decreased when combined with Tolnaftate.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Toloxatone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Buspirone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Buspirone.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Buspirone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Buspirone.Approved
TrazodoneBuspirone may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.Approved, Vet Approved
TrimetrexateThe metabolism of Buspirone can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triprolidine.Approved
TroleandomycinThe metabolism of Buspirone can be decreased when combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Buspirone.Investigational
TylosinThe metabolism of Buspirone can be decreased when combined with Tylosin.Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Buspirone is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Buspirone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Buspirone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Buspirone.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Buspirone.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Buspirone.Approved
VenlafaxineBuspirone may increase the serotonergic activities of Venlafaxine.Approved
VerapamilThe metabolism of Buspirone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Buspirone is combined with Vigabatrin.Approved
VilazodoneBuspirone may increase the serotonergic activities of Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Buspirone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Buspirone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Buspirone.Approved
VoriconazoleThe metabolism of Buspirone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineBuspirone may increase the serotonergic activities of Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Buspirone can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Buspirone.Approved
ZimelidineBuspirone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Buspirone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Buspirone.Approved, Investigational
ZolpidemBuspirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Buspirone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Always take at the same time with respect to meals.
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Take with food.
References
Synthesis Reference

DrugSyn.org

US3717634
General ReferencesNot Available
External Links
ATC CodesN05BE01
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelDownload (275 KB)
MSDSDownload (75.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier+0.9839
Caco-2 permeable-0.538
P-glycoprotein substrateSubstrate0.5726
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8282
Renal organic cation transporterInhibitor0.598
CYP450 2C9 substrateNon-substrate0.8703
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6728
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.7186
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.6277
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.987
Rat acute toxicity2.8167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7042
hERG inhibition (predictor II)Inhibitor0.6914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb co pharmaceutical research institute
  • Actavis totowa llc
  • Apotex inc
  • Dr reddys laboratories ltd
  • Egis pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
TabletOral7.5 mg/1
TabletOral5 mg
Prices
Unit descriptionCostUnit
Wellbutrin xl 300 mg tablet8.68USD tablet
Wellbutrin xl 150 mg tablet6.58USD tablet
Buspar 30 mg tablet5.52USD tablet
Buspirone hcl powder4.74USD g
Buspirone hcl 30 mg tablet3.71USD tablet
Buspar 15 mg tablet3.07USD tablet
Buspirone hcl 15 mg tablet2.16USD tablet
Buspar 10 mg tablet2.05USD tablet
Buspirone hcl 7.5 mg tablet1.62USD tablet
Buspirone hcl 10 mg tablet1.42USD tablet
Buspar 5 mg tablet1.18USD tablet
Vanspar 7.5 mg tablet1.18USD tablet
Buspar 10 mg Tablet1.12USD tablet
Buspirone hcl 5 mg tablet0.79USD tablet
Apo-Buspirone 10 mg Tablet0.62USD tablet
Novo-Buspirone 10 mg Tablet0.62USD tablet
Nu-Buspirone 10 mg Tablet0.62USD tablet
Pms-Buspirone 10 mg Tablet0.62USD tablet
Ratio-Buspirone 10 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point201.5-202.5 °CNot Available
water solubility21.4 mg/LNot Available
logP2.63TAKACS-NOVAK,K 1995 (IN PRESS)
Predicted Properties
PropertyValueSource
Water Solubility0.588 mg/mLALOGPS
logP1.95ALOGPS
logP1.78ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area69.64 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity108.89 m3·mol-1ChemAxon
Polarizability44.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-004i-6940000000-197b8ea9ac79cbda753bView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Azaspirodecanedione
  • Azaspirodecane
  • Dialkylarylamine
  • Piperidinedione
  • N-alkylpiperazine
  • Piperidinone
  • Dicarboximide
  • Delta-lactam
  • Pyrimidine
  • Piperidine
  • Carboxylic acid imide, n-substituted
  • Heteroaromatic compound
  • Carboxylic acid imide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. de Boer SF, Lesourd M, Mocaer E, Koolhaas JM: Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J Pharmacol Exp Ther. 1999 Mar;288(3):1125-33. [PubMed:10027850 ]
  2. Rehman J, Kaynan A, Christ G, Valcic M, Maayani S, Melman A: Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor. Brain Res. 1999 Mar 13;821(2):414-25. [PubMed:10064829 ]
  3. Liang KC: Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors. Eur J Neurosci. 1999 May;11(5):1491-500. [PubMed:10215901 ]
  4. Becker C, Hamon M, Benoliel JJ: Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology. 1999 Apr;38(4):525-32. [PubMed:10221756 ]
  5. Dupuis DS, Tardif S, Wurch T, Colpaert FC, Pauwels PJ: Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein. Neuropharmacology. 1999 Jul;38(7):1035-41. [PubMed:10428422 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Osei-Owusu P, Scrogin KE: Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage. J Pharmacol Exp Ther. 2004 Jun;309(3):1132-40. Epub 2004 Feb 9. [PubMed:14769835 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H: Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003 Jun;75(1):77-82. [PubMed:12781354 ]
  2. Boido A, Boido CC, Sparatore F: Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes. Farmaco. 2001 Apr;56(4):263-75. [PubMed:11421254 ]
  3. Nader MA, Hannemann M: Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons. Behav Pharmacol. 1993 Jun;4(3):263-268. [PubMed:11224194 ]
  4. Pache DM, Fernandez-Perez S, Sewell RD: Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task. Eur J Pharmacol. 2003 Sep 23;477(3):205-11. [PubMed:14522358 ]
  5. Fernandez-Perez S, Pache DM, Sewell RD: Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur J Pharmacol. 2005 Oct 17;522(1-3):78-83. Epub 2005 Oct 7. [PubMed:16214127 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23